Ovarian cancer is a most lethal gynecologic tumor. The mainstay treatment is cytoreductive surgery followed by platinum-based chemotherapy. However, a high percentage of patients recur, thus needing multiple treatments with a frequently poor prognosis. In the last two decades, research has focused on the potential of target therapies to improve the survival of patients affected by ovarian cancer. Bevacizumab is one of the most studied target therapies, and it is approved for first- and second-line treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal tumors. Despite its widespread use with favorable results, controversy regarding patient selection and the best schedule, dosage, and timing of bevacizumab still exists. This review summarizes the state of the art on the use of bevacizumab for ovarian cancer in front-line, recurrence, and neoadjuvant settings. This study focuses on the results of pivotal trials, emerging data, ongoing research, and still unanswered questions about the most adequate dosage of bevacizumab and its potential activity after disease progression or rechallenge in previously treated patients.

Bevacizumab in ovarian cancer: state of the art and unanswered questions / Musella, Angela; Vertechy, Laura; Romito, Alessia; Marchetti, Claudia; Giannini, Andrea; Sciuga, Valentina; Bracchi, Carlotta; Tomao, Federica; DI DONATO, Violante; DE FELICE, Francesca; Monti, Marco; Muzii, Ludovico; BENEDETTI PANICI, Pierluigi. - In: CHEMOTHERAPY. - ISSN 0009-3157. - STAMPA. - 62:2(2016), pp. 111-120. [10.1159/000448942]

Bevacizumab in ovarian cancer: state of the art and unanswered questions

MUSELLA, ANGELA
Primo
;
VERTECHY, LAURA
Secondo
;
ROMITO, ALESSIA;MARCHETTI, CLAUDIA;GIANNINI, ANDREA;SCIUGA, VALENTINA;BRACCHI, CARLOTTA;TOMAO, FEDERICA;DI DONATO, VIOLANTE;DE FELICE, FRANCESCA;MONTI, Marco;MUZII, LUDOVICO
Penultimo
;
BENEDETTI PANICI, PIERLUIGI
Ultimo
2016

Abstract

Ovarian cancer is a most lethal gynecologic tumor. The mainstay treatment is cytoreductive surgery followed by platinum-based chemotherapy. However, a high percentage of patients recur, thus needing multiple treatments with a frequently poor prognosis. In the last two decades, research has focused on the potential of target therapies to improve the survival of patients affected by ovarian cancer. Bevacizumab is one of the most studied target therapies, and it is approved for first- and second-line treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal tumors. Despite its widespread use with favorable results, controversy regarding patient selection and the best schedule, dosage, and timing of bevacizumab still exists. This review summarizes the state of the art on the use of bevacizumab for ovarian cancer in front-line, recurrence, and neoadjuvant settings. This study focuses on the results of pivotal trials, emerging data, ongoing research, and still unanswered questions about the most adequate dosage of bevacizumab and its potential activity after disease progression or rechallenge in previously treated patients.
bevacizumab; chemotherapy; epithelial ovarian cancer; targeted therapies; oncology; pharmacology
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Bevacizumab in ovarian cancer: state of the art and unanswered questions / Musella, Angela; Vertechy, Laura; Romito, Alessia; Marchetti, Claudia; Giannini, Andrea; Sciuga, Valentina; Bracchi, Carlotta; Tomao, Federica; DI DONATO, Violante; DE FELICE, Francesca; Monti, Marco; Muzii, Ludovico; BENEDETTI PANICI, Pierluigi. - In: CHEMOTHERAPY. - ISSN 0009-3157. - STAMPA. - 62:2(2016), pp. 111-120. [10.1159/000448942]
File allegati a questo prodotto
File Dimensione Formato  
Musella_Bevacizumab_2017.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 151.15 kB
Formato Adobe PDF
151.15 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/911467
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 11
social impact